ImmunologybioRxiv
Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor Efficacy
M. G. Lechner, A. Y. Patel, W. Hugo…·M. A. Su
This study shows that inhibiting the IL-17A axis reduces immune-related adverse events in checkpoint inhibitor-treated mice without affecting anti-tumor efficacy.
DOI 10.4049/jimmunol.2200244